Winald R. Gerritsen
About
Winald R. Gerritsen is a scholar working on Oncology, Molecular Biology and Genetics.
According to data from OpenAlex, Winald R. Gerritsen has authored 189 papers receiving a total of 9.3k indexed citations (citations by other indexed papers that have themselves been cited), including 138 papers in Oncology, 60 papers in Molecular Biology and 58 papers in Genetics. Recurrent topics in Winald R. Gerritsen's work include Cancer Immunotherapy and Biomarkers (63 papers), Virus-based gene therapy research (55 papers) and Immunotherapy and Immune Responses (48 papers). Winald R. Gerritsen is often cited by papers focused on Cancer Immunotherapy and Biomarkers (63 papers), Virus-based gene therapy research (55 papers) and Immunotherapy and Immune Responses (48 papers). Winald R. Gerritsen collaborates with scholars based in Netherlands, United States and France. Winald R. Gerritsen's co-authors include Victor W. van Beusechem, Herbert M. Pinedo, David I. Quinn, I. Jolanda M. de Vries, Ronald de Wit, Howard Gurney, Lawrence Fong, Yves Fradet, Dean F. Bajorin and Cora N. Sternberg and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.
In The Last Decade
Winald R. Gerritsen
186 papers receiving 9.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Winald R. Gerritsen Netherlands | 44 | 5.4k | 3.2k | 2.8k | 2.2k | 1.8k | 189 | 9.3k | ||
| Richard E. Royal United States | 39 | 8.1k 1.5× | 2.3k 0.7× | 5.7k 2.1× | 1.3k 0.6× | 1.4k 0.7× | 100 | 11.1k | ||
| David L. Bartlett United States | 57 | 5.8k 1.1× | 3.5k 1.1× | 2.9k 1.0× | 1.7k 0.8× | 3.4k 1.9× | 218 | 10.9k | ||
| Gary L. Clayman United States | 67 | 5.7k 1.1× | 5.0k 1.6× | 946 0.3× | 3.4k 1.6× | 1.6k 0.9× | 232 | 13.8k | ||
| Gert Jan Fleuren Netherlands | 61 | 4.8k 0.9× | 3.5k 1.1× | 5.8k 2.1× | 1.6k 0.8× | 780 0.4× | 234 | 12.6k | ||
| Marybeth S. Hughes United States | 31 | 11.4k 2.1× | 2.9k 0.9× | 7.7k 2.8× | 749 0.3× | 2.4k 1.3× | 85 | 13.7k | ||
| Alessandro D. Santin United States | 53 | 4.6k 0.9× | 3.2k 1.0× | 2.4k 0.9× | 796 0.4× | 781 0.4× | 353 | 10.6k | ||
| Lawrence Fong United States | 52 | 8.9k 1.7× | 4.5k 1.4× | 8.2k 3.0× | 2.7k 1.3× | 970 0.5× | 268 | 16.2k | ||
| Neil Senzer United States | 43 | 3.9k 0.7× | 3.6k 1.1× | 1.2k 0.5× | 468 0.2× | 1.7k 0.9× | 176 | 7.8k | ||
| Michele W.L. Teng Australia | 56 | 9.2k 1.7× | 3.6k 1.1× | 8.3k 3.0× | 833 0.4× | 716 0.4× | 95 | 15.0k | ||
| Martijn P. Lolkema Netherlands | 44 | 4.0k 0.7× | 2.9k 0.9× | 1.8k 0.7× | 678 0.3× | 566 0.3× | 188 | 8.2k |
Countries citing papers authored by Winald R. Gerritsen
Since
Specialization
Citations
This map shows the geographic impact of Winald R. Gerritsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Winald R. Gerritsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Winald R. Gerritsen more than expected).
Fields of papers citing papers by Winald R. Gerritsen
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Winald R. Gerritsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Winald R. Gerritsen. The network helps show where Winald R. Gerritsen may publish in the future.
Co-authorship network of co-authors of Winald R. Gerritsen
This figure shows the co-authorship network connecting the top 25 collaborators of Winald R. Gerritsen. A scholar is included among the top collaborators of Winald R. Gerritsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Winald R. Gerritsen. Winald R. Gerritsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Wilpe, Sandra van, Martijn H. den Brok, Harm Westdorp, et al.. (2024). Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial. Annals of Oncology. 35(12). 1126–1137.
2.
Tolmeijer, Sofie H., Sandra van Wilpe, Maartje J. Geerlings, et al.. (2023). Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer. European Urology Oncology. 7(2). 282–291.
3.
Beusechem, Victor W. van, David P. Noske, C. B. H. W. Lamers, et al.. (2022). Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM:A Phase I Clinical Trial Including Correlative Studies. Digital Commons@Becker (Washington University School of Medicine).
4.
Creemers, Jeroen H. A., W. Joost Lesterhuis, Niven Mehra, et al.. (2021). A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery. Journal for ImmunoTherapy of Cancer. 9(5). e002032–e002032.
5.
Tolmeijer, Sofie H., Rutger H.T. Koornstra, Jan Willem B. de Groot, et al.. (2021). Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma. Cancers. 13(15). 3913–3913.
6.
Wilpe, Sandra van, Sofie H. Tolmeijer, Rutger H.T. Koornstra, et al.. (2021). Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity. Cancers. 13(9). 2249–2249.
7.
Mehra, Niven, Gosse J. Adema, Linda G.W. Kerkmeijer, et al.. (2021). 642TiP Phase II CA184-585 (INSPIRE) trial of ipilimumab with nivolumab for molecular-selected patients with castration-resistant prostate cancer. Annals of Oncology. 32. S671–S671.
8.
Bloemendal, Martine, Kalijn F. Bol, Mark A.J. Gorris, et al.. (2021). Immunological responses to adjuvant vaccination with combined CD1c + myeloid and plasmacytoid dendritic cells in stage III melanoma patients. OncoImmunology. 11(1). 2015113–2015113.
9.
Doelen, Maarten J. van der, Hans M. Westgeest, Carin A. Uyl‐de Groot, et al.. (2020). Impact of DNA damage repair defects and aggressive variant features on response to carboplatin‐based chemotherapy in metastatic castration‐resistant prostate cancer. International Journal of Cancer. 148(2). 385–395.
10.
Nilsson, R. Jonas A., Leonora Balaj, Esther Hulleman, et al.. (2019). Supplemental data for Blood platelets contain tumor-derived RNA biomarkers. Pure Amsterdam UMC.
11.
Koornstra, Rutger H.T., Johanna H. M. Driessen, Bas van Vlijmen, et al.. (2018). The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study. Targeted Oncology. 13(3). 363–370.
12.
Bloemendal, Martine, Winald R. Gerritsen, Carl G. Figdor, et al.. (2018). Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy. Clinical & Translational Oncology. 21(6). 774–780.
13.
Petrylak, Daniel P., Nicholas J. Vogelzang, Yves Fradet, et al.. (2017). Subgroup analyses from KEYNOTE-045: Pembrolizumab (pembro) versus individual investigator’s choice of chemotherapy (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (uc). Annals of Oncology. 28. v298–v298.
14.
Bellmunt, Joaquim, Ronald de Wit, David J. Vaughn, et al.. (2017). Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. New England Journal of Medicine. 376(11). 1015–1026.
15.
Hangalapura, Basav N., Dinja Oosterhoff, Jan de Groot, et al.. (2011). Potent Antitumor Immunity Generated by a CD40-Targeted Adenoviral Vaccine. Cancer Research. 71(17). 5827–5837.
16.
Idema, Sander, A.A. Geldof, Clemens M.F. Dirven, et al.. (2007). Evaluation of adenoviral oncolytic effect on glioma spheroids by 18F-DG positron-emission tomography. Oncology Reports. 16(10).
17.
Carette, Jan E., Harm C.A. Graat, Frederik H.E. Schagen, et al.. (2005). Replication‐dependent transgene expression from a conditionally replicating adenovirus via alternative splicing to a heterologous splice‐acceptor site. The Journal of Gene Medicine. 7(8). 1053–1062.
18.
Grill, Jacques, Martine L.M. Lamfers, Victor W. van Beusechem, et al.. (2005). Oncolytic Virotherapy of Meningiomas in Vitro with Replication-competent Adenovirus. Neurosurgery. 56(1). 146–154.
19.
Gruijl, Tanja D. de, Sylvia A. Luykx‐de Bakker, Bryan Tillman, et al.. (2002). Prolonged Maturation and Enhanced Transduction of Dendritic Cells Migrated from Human Skin Explants After In Situ Delivery of CD40-Targeted Adenoviral Vectors. The Journal of Immunology. 169(9). 5322–5331.
20.
Heideman, Daniëlle A.M., Peter J.F. Snijders, Elisabeth Bloemena, et al.. (2001). Absence oftpr-metand expression ofc-metin human gastric mucosa and carcinoma. The Journal of Pathology. 194(4). 428–435.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Richard E. Royal Breakdown of academic impact, for papers by David L. Bartlett Breakdown of academic impact, for papers by Gary L. Clayman Breakdown of academic impact, for papers by Gert Jan Fleuren Breakdown of academic impact, for papers by Marybeth S. Hughes Breakdown of academic impact, for papers by Alessandro D. Santin Breakdown of academic impact, for papers by Lawrence Fong Breakdown of academic impact, for papers by Neil Senzer Breakdown of academic impact, for papers by Michele W.L. Teng Breakdown of academic impact, for papers by Martijn P. Lolkema